About Curasight

First-in-Class Radioligand Therapy Targeting uPAR – the Driver of Cancer Aggressiveness

Curasight is a clinical-stage radiopharmaceutical company developing uTREAT^®, a first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat aggressive solid tumors across multiple indications.

uPAR (urokinase-type plasminogen activator receptor) is broadly expressed in aggressive cancers and is associated with invasion, angiogenesis, and metastasis, enabling a platform-based development strategy built on a shared biological target and shared uPAR-targeting ligand. One target. One therapy. A pipeline-in-a-drug across aggressive solid tumors.

Curasight’s therapeutic platform, uTREAT^®, is supported by uTRACE^®, our clinically validated uPAR PET diagnostic platform built on the same uPAR-targeting ligand. uTRACE^® enables a true theranostic approach by supporting patient selection, confirming tumor targeting, and de-risking therapeutic development through human imaging validation. uTRACE^® is fully developed, GMP-manufactured, and has been evaluated in nine clinical trials involving 450 patients across eight different solid tumor types. This extensive clinical experience provides direct human validation of uPAR as a therapeutic target and demonstrates robust tumor uptake and favorable biodistribution — forming the foundation for uTREAT^®.

The platform is built on more than a decade of rigorous translational research conducted at Copenhagen University Hospital and the University of Copenhagen, providing a strong academic and clinical foundation for Curasight’s first-in-class uPAR targeting approach.

Together, this combination of validated biology, the right radioligand modality, and human clinical proof-of-concept positions uTREAT^® as a next-generation radioligand therapy platform.